Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.
about
HIV-free survival at 12-24 months in breastfed infants of HIV-infected women on antiretroviral treatmentA Systematic Review of Interventions to Reduce Maternal Mortality among HIV-Infected Pregnant and Postpartum WomenRandomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3.Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women.Self-Reported Side Effects and Adherence to Antiretroviral Therapy in HIV-Infected Pregnant Women under Option B+: A Prospective StudyPaediatric HIV: Progress on Prevention, Treatment and CureNo Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.Brief Report: Food Insufficiency Is Associated With Lack of Sustained Viral Suppression Among HIV-Infected Pregnant and Breastfeeding Ugandan Women.Viral Suppression and Retention in Care up to 5 Years After Initiation of Lifelong ART During Pregnancy (Option B+) in Rural Uganda.Advances in therapy for the prevention of HIV transmission from mother to child.Estradiol Levels Are Altered in Human Immunodeficiency Virus-Infected Pregnant Women Randomized to Efavirenz-Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy.Development and Validation of an Assay to Analyze Atazanavir in Human Hair Via Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).What is new in perinatal HIV prevention?Prevention of Hiv-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in Hiv-1-Infected Women with High Cd4 Cell Count (Impaact Promise): A RNovel methods to estimate antiretroviral adherence: protocol for a longitudinal study.Adverse effects of antiretroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study
P2860
Q28070420-02D4E155-7073-425B-96CA-CB6BA822CD26Q30381808-5F02C442-6F94-45A7-90A9-D7026377633CQ33657188-317C85A1-6982-45AD-9384-0E725E7E42E6Q35627832-07EA488D-46C7-4D4F-9CFC-DDA9FE10D7F6Q36167659-6719EDD4-448E-43FB-A2F3-10CAB759A3BEQ36395153-002D50AE-AEEF-4427-B6DF-E206A398E151Q36439051-A94C8734-5352-4F3F-AD6C-FF15AFAF91E4Q36576508-3446DA90-88A0-49EB-9798-D22B6D39F65EQ38852269-02158A97-B9F4-4C35-8BBA-815D7DF26BFCQ39234019-1DED8488-7D21-47B6-B0F0-2BB51DC984AFQ45324863-6AD5F447-E347-4270-9D85-7CCAE7597735Q47724822-BF04C47A-D8B2-4B67-8391-7DBA42E0CD48Q48521585-2F2CB419-9819-42E7-A7C7-CF90151D6B84Q48569593-19787167-0CC6-4A85-BEE8-5E4B21719951Q55311524-B15BFE5A-2CAF-4FA3-A27F-843B40A53DF5Q59128516-A75E1455-E53D-4433-9210-BB011C83DA9D
P2860
Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Efficacy and safety of lopinav ...... fected pregnant Ugandan women.
@ast
Efficacy and safety of lopinav ...... fected pregnant Ugandan women.
@en
type
label
Efficacy and safety of lopinav ...... fected pregnant Ugandan women.
@ast
Efficacy and safety of lopinav ...... fected pregnant Ugandan women.
@en
prefLabel
Efficacy and safety of lopinav ...... fected pregnant Ugandan women.
@ast
Efficacy and safety of lopinav ...... fected pregnant Ugandan women.
@en
P2093
P2860
P50
P1433
P1476
Efficacy and safety of lopinav ...... fected pregnant Ugandan women.
@en
P2093
Albert Plenty
Bridget Nzarubara
Catherine A Koss
Deborah Cohan
Flavia Luwedde
Jane Achan
Monica Gandhi
Paul Natureeba
Tamara D Clark
Theodore Ruel
P2860
P304
P356
10.1097/QAD.0000000000000531
P407
P577
2015-01-01T00:00:00Z